Welcome to our dedicated page for Edesa Biotech news (Ticker: EDSA), a resource for investors and traders seeking the latest updates and insights on Edesa Biotech stock.
Edesa Biotech reports developments as a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases. Its recurring news centers on paridiprubart, or EB05, an anti-TLR4 antibody evaluated for Acute Respiratory Distress Syndrome, and EB06, an anti-CXCL10 monoclonal antibody program for moderate-to-severe nonsegmental vitiligo.
Company updates also cover clinical data presentations, manufacturing and regulatory preparation, government-supported research activities, conference participation, operating results, capital-structure matters and shareholder governance. Financial reports generally frame spending around clinical development priorities and the company’s monoclonal antibody pipeline.
Edesa Biotech (NASDAQ:EDSA) announced the completion of over 50% patient enrollment for the Phase 2 portion of its Phase 2/Phase 3 clinical study of EB05, aimed at treating hospitalized COVID-19 patients at risk of developing Acute Respiratory Distress Syndrome (ARDS). Over 160 out of 316 planned subjects have been randomized. The company is accelerating the process by activating approximately 20 more hospital sites. Dr. Par Nijhawan highlighted the unmet medical need for ARDS treatment, emphasizing the importance of this milestone in their efforts to address severe cases of COVID-19.
Edesa Biotech (NASDAQ:EDSA) recently announced the completion of enrollment for the first cohort in its Phase 2b clinical study of EB01, targeting chronic Allergic Contact Dermatitis (ACD). A total of 46 subjects were randomized and treated with either EB01 or a placebo. EB01, an sPLA2 inhibitor, aims to reduce inflammation without steroid-related safety concerns. The company will conduct a blinded interim analysis post a 28-day treatment period. Edesa is optimistic about the drug's potential, and if the interim results are favorable, the final study phase will proceed.
Edesa Biotech, Inc. (NASDAQ:EDSA) has successfully closed an underwritten public offering, selling 1,562,500 common shares at $6.40 each, totaling $10 million in gross proceeds. The offering allows for an additional 234,375 shares to be purchased by the underwriter within 30 days. Proceeds will be directed toward general corporate expenses, including capital expenditures and R&D. The company is developing treatments for inflammatory diseases, notably EB05 for ARDS and EB01 for allergic dermatitis. The registration statement for this offering has been effective since September 12, 2019.
Edesa Biotech, Inc. (Nasdaq:EDSA) announced an increased public offering of 1,562,500 common shares at $6.40 each, expected to close around March 2, 2021. The offering aims to raise approximately $10 million for general corporate purposes, including working capital and R&D expenses. H.C. Wainwright & Co. is the book-running manager, with an option for the underwriter to purchase an additional 234,375 shares. This follows a previously declared effective registration statement with the SEC.
Edesa Biotech, Inc. (Nasdaq:EDSA) has entered an underwriting agreement with H.C. Wainwright & Co. for the purchase of 546,875 common shares at $6.40 each. The offering, expected to close by March 2, 2021, aims to raise approximately $3.5 million. Edesa intends to utilize the net proceeds for general corporate purposes, which may include working capital and R&D expenses. Additionally, the underwriter holds a 30-day option for an extra 82,031 shares. The offering is made via a prospectus supplement filed with the SEC.
Edesa Biotech, Inc. (NASDAQ:EDSA) reported financial results for Q1 2021, ending December 31, 2020. The company announced a C$14 million grant from the Canadian government to support its Phase 2 clinical study of EB05 for Acute Respiratory Distress Syndrome (ARDS), associated with COVID-19. Edesa has no revenues for the quarter, with a net loss of $2.64 million or $0.26 per share. Operating expenses rose to $2.61 million, reflecting ongoing R&D efforts. Edesa aims for an interim analysis of the ARDS study soon, while also progressing in a Phase 2b study for chronic allergic contact dermatitis.
Edesa Biotech (NASDAQ:EDSA) has received FDA and Health Canada approval for a sub-study in its Phase 2/3 clinical trial of EB05, aimed at treating Acute Respiratory Distress Syndrome (ARDS) in critically ill COVID-19 patients. This sub-study will include up to 100 ICU patients whose conditions disqualify them from the main study. EB05 works by inhibiting TLR4 signaling, potentially reducing lung inflammation and injury. The ongoing study plans to enroll up to 316 patients, with promising results possibly leading to a pivotal Phase 3 trial.
Edesa Biotech, Inc. (NASDAQ:EDSA) announced that CEO Dr. Par Nijhawan will join a virtual panel discussion titled Canadian Innovative COVID Solutions on January 26, 2021, at 2:20 PM ET. The event, organized by Clinical Trials Ontario, will focus on developing multiple countermeasures to the COVID-19 pandemic, including Edesa's EB05 drug candidate designed to treat Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. Edesa is advancing innovative treatments for inflammatory and immune-related diseases, with EB05 currently in late-stage clinical studies.
Edesa Biotech (NASDAQ:EDSA) has secured approval from Colombia's Ministry of Health to expand its clinical trial for the investigational drug EB05 in hospitalized COVID-19 patients. The trial, already underway in the U.S. and Canada, aims to evaluate EB05's efficacy in modulating immune response associated with Acute Respiratory Distress Syndrome (ARDS). About 316 patients will be enrolled across various sites in Colombia, with results expected to facilitate a subsequent Phase 3 study. This initiative demonstrates Edesa's commitment to address significant unmet needs in COVID-19 treatment.
Edesa Biotech, Inc. (NASDAQ:EDSA) reflected on a challenging yet productive 2020 in a letter to shareholders from CEO Par Nijhawan. Despite the global pandemic, the company made strides in expanding its development pipeline, acquiring global rights to key monoclonal antibody candidates. Regulatory approvals were obtained for clinical studies targeting COVID-19, and the Phase 2/3 study for EB05 was launched. Edesa also reported encouraging patient recruitment for its Allergic Contact Dermatitis study. The company is focused on efficiently utilizing its capital and prioritizing projects that meet significant medical needs.